Literature DB >> 8461470

Induction of monocytic differentiation and tumorigenicity by v-Ha-ras in differentiation arrested hematopoietic cells.

S Hibi1, J Löhler, J Friel, C Stocking, W Ostertag.   

Abstract

Activated ras genes are often associated with human myeloid leukemias with a monocytic differentiated phenotype. To investigate the role of the activated ras gene in leukemogenesis, a myeloid nontumorigenic cell line (FDC-P1) was infected with a selectable retroviral vector carrying the v-Ha-ras gene (H1neo). Infected FDC-P1 cells were not only tumorigenic, but also showed increased monocytic differentiation in vitro. Monocytic differentiation and tumorigenicity in vivo were correlated with several-fold increased levels of activated ras gene expression. Tumorigenic cells were arrested with respect to monocytic marker expression at a much later stage of macrophage differentiation than the parental noninfected FDC-P1 cells. These data thus suggest a model of how activated ras genes could be involved in the preferential induction of hematopoietic malignancies with a myelomonocytic phenotype.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461470

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Alterations in differentiation and behavior of monocytic phagocytes in transgenic mice that express dominant suppressors of ras signaling.

Authors:  D I Jin; S B Jameson; M A Reddy; D Schenkman; M C Ostrowski
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

Review 2.  Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.

Authors:  René Huber; Daniel Pietsch; Johannes Günther; Bastian Welz; Nico Vogt; Korbinian Brand
Journal:  Cell Mol Life Sci       Date:  2013-03-24       Impact factor: 9.261

Review 3.  Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.

Authors:  Wei Pan; Qian Sun; Yang Wang; Jian Wang; Shui Cao; Xiubao Ren
Journal:  Tumour Biol       Date:  2015-04-01

4.  Involvement of the protein tyrosine phosphatase SHP-1 in Ras-mediated activation of the mitogen-activated protein kinase pathway.

Authors:  S Krautwald; D Büscher; V Kummer; S Buder; M Baccarini
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

5.  Scaffolding protein Gab2 mediates differentiation signaling downstream of Fms receptor tyrosine kinase.

Authors:  Y Liu; B Jenkins; J L Shin; L R Rohrschneider
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

6.  Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition.

Authors:  Craig Dorrell; Katsuto Takenaka; Mark D Minden; Robert G Hawley; John E Dick
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 7.  Signaling pathways involved in MDSC regulation.

Authors:  Prashant Trikha; William E Carson
Journal:  Biochim Biophys Acta       Date:  2014-04-13

8.  Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.

Authors:  Zhenyun Yang; Takako Kondo; Cara S Voorhorst; Sarah C Nabinger; Leila Ndong; Fuqin Yin; Edward M Chan; Menggang Yu; Oliver Würstlin; Christian P Kratz; Charlotte M Niemeyer; Christian Flotho; Eri Hashino; Rebecca J Chan
Journal:  Mol Cell Biol       Date:  2009-06-15       Impact factor: 4.272

9.  Shc, Grb2, Sos1, and a 150-kilodalton tyrosine-phosphorylated protein form complexes with Fms in hematopoietic cells.

Authors:  M N Lioubin; G M Myles; K Carlberg; D Bowtell; L R Rohrschneider
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

10.  Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Authors:  Mona Meyer; Daniela Rübsamen; Robert Slany; Thomas Illmer; Kathleen Stabla; Petra Roth; Thorsten Stiewe; Martin Eilers; Andreas Neubauer
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.